Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators
Citations Over TimeTop 10% of 2013 papers
Abstract
Adenosine 5'-monophosphate-activated protein kinase (AMPK) is emerging as a promising drug target for its regulatory function in both glucose and lipid metabolism. Compound PT1 (5) was originally identified from high throughput screening as a small molecule activator of AMPK through the antagonization of the autoinhibition in α subunits. In order to enhance its potency at AMPK and bioavailability, structure-activity relationship studies have been performed and resulted in a novel series of AMPK activators based on an alkene oxindole scaffold. Following their evaluation in pharmacological AMPK activation assays, lead compound 24 was identified to possess improved potency as well as favorable pharmacokinetic profile. In the diet-induced obesity (DIO) mouse model, compound 24 was found to improve glucose tolerance and alleviate insulin resistance. The in vitro and in vivo data for these alkene oxindoles warrant further studies for their potential therapeutic medications in metabolic associated diseases.
Related Papers
- → Alkene Hydrofunctionalization Using Hydroxamic Acids: A Radical-Mediated Approach to Alkene Hydration(2014)25 cited
- → In-depth insight into metal–alkene bonding interactions(2006)19 cited
- → Novel head-to-tail alkyl-alkene or alkene-alkene coupling via zirconium-catalyzed reaction of alkylmagnesium derivatives with monosubstituted alkenes(1992)46 cited
- → Influence of alkene structure on the formation constants of alkene–ICl molecular complexes(1986)5 cited
- → Baeyer Oxindole Synthesis(2010)